Synairgen Revenue and Competitors
Estimated Revenue & Valuation
- Synairgen's estimated annual revenue is currently $4.3M per year.
- Synairgen's estimated revenue per employee is $155,000
Employee Data
- Synairgen has 28 Employees.
- Synairgen grew their employee count by 4% last year.
Synairgen's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Commercial Officer | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | VP Clinical QA | Reveal Email/Phone |
4 | Head Clinical Operations | Reveal Email/Phone |
5 | Quality Director | Reveal Email/Phone |
6 | Chief Scientific Officer | Reveal Email/Phone |
7 | Chief Regulatory Officer | Reveal Email/Phone |
8 | HR Manager | Reveal Email/Phone |
9 | Quality Systems Manager | Reveal Email/Phone |
10 | Senior CTA | Reveal Email/Phone |
Synairgen Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $46850M | 145000 | 16% | $20.2B | $539B |
#2 | $5880M | 6107 | 4% | $400M | $31.1B |
What Is Synairgen?
Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Synairgen is currently running a Phase II trial evaluating SNG001 in COPD patients and announced on 18 March 2020 a Phase II trial with SNG001 in COVID-19 patients to potentially assist with the global outbreak. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com
keywords:N/A
N/A
Total Funding
28
Number of Employees
$4.3M
Revenue (est)
4%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Synairgen News
SOUTHAMPTON, England, April 5, 2022 /PRNewswire/ -- Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational...
Synairgen to present further analysis of Phase 3 SPRINTER trial in hospitalised patients with COVID-19 at the ATS 2022 International Conference.
Synairgen shares have fallen by 88.7% in 2022. What's next for the firm? · The plunge was triggered by clinical trial results for its COVID-19...
Other Companies in Southampton
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $5.7M | 28 | -3% | N/A |
#2 | $4.4M | 32 | 39% | N/A |
#3 | $3.1M | 32 | 33% | N/A |
#4 | $6.7M | 33 | -8% | N/A |
#5 | $7.3M | 34 | N/A | N/A |